Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
MET heads into its November 4 earnings date with a rare burst of analyst conviction behind it, even as the stock trades nearly a decade behind its mean price target.
A cluster of target-price raises has landed this week, and the direction is clear. Barclays lifted its target from $97 to $111 in one move, maintaining Overweight. UBS and TD Cowen both raised to $110, from $105, keeping Buy ratings. Mizuho is the lone dissenter, trimming its target modestly from $112 to $109 while holding Outperform. The consensus mean target now stands at $107.38, roughly 10% above Monday's close of $97.16. Piper Sandler upgraded outright to Overweight from Neutral in late September, adding further weight to the bullish shift. The Street's positioning on forward earnings is striking: MET ranks in the 95th percentile on both analyst recommendation momentum and 12-month forward EPS growth expectations, two signals that are rarely this well aligned at the same time.
The borrowing market tells a completely different story, and it is worth pausing on. Short interest is negligible at just under 1.9% of the free float, a level that simply does not register as a meaningful bearish signal. Borrow availability is effectively uncapped, with hundreds of millions of shares available to lend, far beyond what any short-selling campaign would need. Cost to borrow has nudged up around 22% week-on-week to 0.41%, but in absolute terms that remains exceptionally cheap. The ORTEX short score of 33.7 has been virtually flat for two weeks, with no meaningful build in short positioning. Options positioning is also unremarkable: the put/call ratio of 1.44 is essentially in line with its 20-day average of 1.44, with a z-score close to zero. In short, neither the borrow market nor the options market shows any hedging pressure building into November.
The valuation backdrop is modest but not cheap. The trailing P/E is around 8.9x and the price-to-book is just under 2.0x, with both multiples edging up on the week. The earnings yield factor score is low at the 13th percentile on EV/EBIT, suggesting the market is not pricing MET as a deep-value play despite the below-market multiple. The 30-day EPS momentum score at the 87th percentile points to sustained upward revisions. Q2 results, reported in early August, produced a roughly 4% one-day gain in the stock. The 5-day drift after that print was more muted at just over half a percent, suggesting the market absorbed the news quickly rather than continuing to re-rate.
Among peers, performance this week has been mixed. LNC and UNM both posted gains of around 3% and 4% respectively on the week, tracking closer to MET's own 2% rise. PFG and FNF lagged, down 3.7% and 5.1%. PRU slipped about 1.3%. MET's relative outperformance against the broader peer group over the year-to-date period remains intact according to recent data, with the stock up roughly 20% in 2026 while several correlated names have struggled. The activist register carries one notable entry: the MetLife Policyholder Trust, which holds 16.1% of shares via a Schedule 13D, filed most recently in August. This is the company's own internal structure rather than an external activist, though as with all 13D/G disclosures, the stake is as-last-disclosed and positions below 5% can exit without further filing.
Wikipedia attention for MET is running notably above its own 90-day average, with a z-score of 1.81 as of late September, the highest retail-attention reading in the dataset. This is a measure of attention, not a revenue signal, but the elevated interest coincides directly with the recent analyst upgrade cycle.
The next earnings print on November 4 is the clearest near-term marker, and with targets now clustered between $108 and $111, the conversation between bulls and the market will centre on whether investment income can close the gap left by the Q2 miss.
See the live data behind this article on ORTEX.
Open MET on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
